AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04750278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study NCT05205629 — intervention group
Intervention type: DRUG
Intervention: Donafenib combined with TACE
Description: Donafenib(200mg bid po) combined with TACE
Study NCT05559632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: osteotomy for implant placement
Description: preparing the bone for implant placement
Study NCT05559632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteotomy for implant placement
Description: preparing the bone for implant placement
Study NCT04666363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender oil
Description: the essence was diluted 1:10 with sweet almond oil. A cotton ball soaked in 3 drops of diluted lavender essence was kept at a 10 cm distance from the patients' nose and they were asked to breathe slowly for 5 min.
Study NCT06544369 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccin
Description: injection
Study NCT04831996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered orally after 8 hours of fasting.
Study NCT03747718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
Study NCT03747718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
Study NCT06133959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The-Optimal-Lymph-Flow (TOLF) Program
Description: TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.
Study NCT06133959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The-Optimal-Lymph-Flow (TOLF) Program
Description: TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.
Study NCT05565885 — intervention group
Intervention type: OTHER
Intervention: Sampling
Description: 4 blood sampling per patient and an additional one in case of relapse
Study NCT05750836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific nursing support
Description: * 3 mandatory on-site nursing consultations with the patient's caregiver at inclusion, 6 months and 12 months post-randomisation.The caregivers will complete the questionnaires (Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36, Caregiver's satisfaction).~* interviews once a month with a nurse either by phone, on-site consultation or teleconsultation.~Nurses assess the general health of the caregiver and Identify the socio-professional situation of the caregiver
Study NCT05750836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-specific nursing support
Description: Caregivers will only have to complete on site Health indicators, Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36 at inclusion, 6 months and 12 months post-randomisation.
Study NCT04947514 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic acid
Description: Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.
Study NCT04947514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (topical saline)
Description: The untreated breast will receive topical saline.
Study NCT05006326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Intravenous access is established in advance, intravenous bolus injection, 68Ga-PSMA dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg). Patients were encouraged to drink water after injection and asked to empty their bladder before PET scan.
Study NCT05006326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
Study NCT05006326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
Study NCT05730309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized discharge and expedited referral instructions
Description: The intervention for subjects with LVH on research POCUS will consist of three elements: 1) disclosure of presence of LVH to subject, ED team and primary care physician (PCP) (if applicable); 2) educational discharge instructions describing high BP, HTN, LVH, implications for development of cardiovascular disease (such as development of heart failure, stroke), options for treatment (lifestyle, medications) and importance of follow-up; A preliminary version will be refined prior to the start of the trial by feedback from ED physicians and patients. Refinement will target content, phrasing, and literacy level. 3) referral to outpatient care, consisting of one of two options, based on whether the subject has an established PCP. For subjects with existing PCP, the study team will call the office, inform about study participation, LVH findings, and secure a follow-up appointment. For those with no PCP, study team will arrange for follow-up to special clinic.
Study NCT04554745 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: ultrasound assessment of pregnant women
Study NCT05891145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is dispensed at 2 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
Study NCT05891145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Midazolam is dispensed at 1 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
Study NCT05336175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain. This substance is naturally produced in the body and works by activating areas in the brain involved in memory. Previous studies examining the ability of Ang-(1-7) treatment to prevent memory loss post open-heart surgery found that 21 days of treatment with Ang-(1-7) protected memory post-surgery. Participants treated with Ang-(1-7) were protected from post-surgery increase in NfL levels. This clinical sub-project within the existing study will allow us to obtain preliminary data to evaluate the safety and efficacy of treatment with Ang-(1-7) to improve cognitive function and determine if this treatment is associated with changes in plasma levels of NfL protein.30 participants will take 100 micrograms of Ang-(1-7) per day via subcutaneous injection for 90 days.
Study NCT05336175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution will be given as a placebo intervention to 10 participants. These participants will take 100 micrograms of saline solution per day via subcutaneous injection for 90 days.
Study NCT05482191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the treatment group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses~* Diet and exercise instruction by professional nutritionist using internet applet~* Take part in sports activities that are organized by the sports health teacher during school hours.
Study NCT04075786 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Each participant will be shown 40 (forty) 3D ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3D ultrasound and associated infertility (T, Y or I shaped).
Study NCT05713695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full MISSION
Description: MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery.
Study NCT05713695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linkage Only Delivered by a Peer Specialist
Description: Linkage only is provided via Peer Specialists whom have lived experiences similar to that of our participants. Linkage only includes informal treatment planning and linkages and supports to needed community services.
Study NCT05143164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydrocolloid dressing
Description: Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.
Study NCT05143164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin Sulfate, Topical
Description: Application of gentamicin to exit site daily
Study NCT05105048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with saline
Study NCT05105048 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT05671497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 MG
Description: An antiplatelet agent used for intermittent claudication , it has an anti-inflammatory effect which will help control patients with Rheumatoid arthritis
Study NCT05671497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional synthetic antirheumatic drugs
Description: methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily
Study NCT05671497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional synthetic antirheumatic drugs
Description: methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily
Study NCT05825222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E-PR-01 (Low dose)
Description: One Capsule to be consumed twice a day
Study NCT05825222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E-PR-01 (High Dose)
Description: One Capsule to be consumed twice a day
Study NCT05825222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Capsule to be consumed twice a day
Study NCT05735665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bowel ultrasound
Description: Bowel US is a non-invasive tool which is able to measure intestinal inflammation by the use of emission of US from a specific probe. It is used externally, just moving the probe on the skin of the patient along the abdominal section. It does not require any contrast. The preparation used is just a fasting period of 6 hours.
Study NCT05735665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: colonoscopy
Description: Colonoscopy is an endoscopic procedure where a tube is inserted from the anus up to the ileum of the patient. It requires bowel cleansing with polyethilenglicole up to 4 liters (depending on the preparation and the desired grade of cleansing) the day before the examination. Because it may be painful, usually sedation is provided.
Study NCT05776290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: This material will be injected into the prepared impact socket prior to inserting the implant. This injection will be done inside the socket as well as on the periphery of the socket.
Study NCT05442450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral semaglutide
Description: Participants in Experimental group will receive oral Semaglutide along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on patient tolerance.
Study NCT05390177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video type
Description: One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
Study NCT05390177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video type
Description: One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
Study NCT06492772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: experimental group
Description: The experimental group will be asked to use a mobile smoking cessation application based on the transtheoretical model. Individuals will be required to use the mobile application for 6 months. Measurements will be made at 1, 3, and 6 months.
Study NCT06492772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: The experimental group will be asked to use a mobile smoking cessation application based on the transtheoretical model. Individuals will be required to use the mobile application for 6 months. Measurements will be made at 1, 3, and 6 months.
Study NCT06120868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surefil one®
Description: For Surefil one® restorations, the capsule will be activated by pressing it against a stable surface, then mixed in a capsule mixer for 10 s. The capsule tip will be inserted into the proximal box, and the material is extruded as the tip is gradually moved in a coronal direction, ensuring that the material adapts to the cavity bottom and walls.
Study NCT06120868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtek One
Description: Scotchbond™ Universal (SBU) will be used as an adhesive system in self-etch mode for FiltekTM One restoration. SBU will be applied actively for 20 seconds with a disposable brush tip, air-dried gently for 5 seconds to create a consistent bond thickness, then light-cured for 10 seconds. The FiltekTM One will be packed in increments up to 4 mm thick. A second layer of FiltekTM One will be applied on top of the first 4-mm layer if 4 mm is not adequate to properly restore the tooth. Each increment will be light cured for 20 seconds.
Study NCT06543563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: After the craniotomy, a continuous infusion of ketamine at a rate of 0.3 mg/kg/h (0.3 ml/kg/h) is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
Study NCT06543563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: After the craniotomy, a continuous infusion of normal saline at a rate of 0.3 ml/kg/h is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
Study NCT05133583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: The experimental group was interviewed in an online meeting prepared by a certified LY trainer.~She received LY exercises once a week (40 minutes per session) for 6 weeks (6 sessions). Each The meeting was organized with a maximum of 12 people.
Study NCT05994976 — intervention group
Intervention type: PROCEDURE
Intervention: Blood samples collection
Description: biomarkers and optional genetic analysis
Study NCT05994976 — intervention group
Intervention type: PROCEDURE
Intervention: Oral samples collection
Description: biomarkers analysis
Study NCT05994976 — intervention group
Intervention type: PROCEDURE
Intervention: Hair samples collection
Description: biomarkers analysis
Study NCT05994976 — intervention group
Intervention type: PROCEDURE
Intervention: Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping)
Description: biomarkers analysis
Study NCT05994976 — intervention group
Intervention type: PROCEDURE
Intervention: Skin surface material samples
Description: biomarkers analysis
Study NCT05994976 — intervention group
Intervention type: PROCEDURE
Intervention: Drainage fluid samples collection
Description: biomarkers analysis
Study NCT05994976 — intervention group
Intervention type: PROCEDURE
Intervention: Stool samples collection
Description: biomarkers analysis
Study NCT05325372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary block
Description: it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
Study NCT05325372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infraclavicular block
Description: it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
Study NCT04684108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG301
Description: Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
Study NCT05421468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-Thyroxine time B (5-15 minutes Before dawn)
Description: Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
Study NCT05421468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: L-Thyroxine time B (5-15 minutes Before dawn)
Description: Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
Study NCT05638347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7085 tablets
Description: Single oral administration
Study NCT05638347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Single oral administration
Study NCT05396937 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multifocal Stereotactic Radiotherapy
Description: Radiotherapy will be given in combination with atezolizumab and bevacizumab. The patient will be initially treated with atezolizumab and bevacizumab after enrollment. Radiotherapy will be administered to the metastases 1-2 weeks after the completion of the first intravenous injection of atezolizumab and bevacizumab, in the mode of multifocal stereotactic radiotherapy, with a planned total dose to the planned target volume of 25-50 Gy in five divided doses of 5-10 Gy/fraction. Systemic therapy could be continued 48 hours after completion of radiotherapy.
Study NCT05396937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection [Tecentriq]
Description: Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
Study NCT05396937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle
Study NCT05331469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH basal insulin titration
Description: Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months